Afdhal N H, Esteban R
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Aliment Pharmacol Ther. 2007 Nov;26 Suppl 1:1-4. doi: 10.1111/j.1365-2036.2007.03508.x.
Thrombocytopenia is a common hematologic toxicity among patients with chronic liver disease.
To give a brief overview of thrombocytopenia and its effects on patients with chronic liver disease.
Thrombocytopenia is generally mild to moderate in severity and can thus be managed relatively easily. Severe thrombocytopenia (platelet count <50,000 /microL), however, may present significant challenges to patient management. Thrombocytopenia can increase the risk of bleeding associated with invasive or surgical procedures. Therefore, while perhaps less widely appreciated than the impact of anemia or neutropenia, effective prevention and management of thrombocytopenia is also critical for patients with liver disease.
This supplement to Alimentary Pharmacology & Therapeutics provides a comprehensive review of the significance of thrombocytopenia in patients with chronic liver disease, its pathophysiology and relationship to coagulation disorders, impact on clinical care and resource utilization, and novel therapies that may be able to supplant platelet transfusions.
血小板减少症是慢性肝病患者中常见的血液学毒性反应。
简要概述血小板减少症及其对慢性肝病患者的影响。
血小板减少症的严重程度一般为轻度至中度，因此相对易于处理。然而，严重血小板减少症（血小板计数<50,000/微升）可能给患者管理带来重大挑战。血小板减少症会增加与侵入性或外科手术相关的出血风险。因此，虽然血小板减少症的影响可能不如贫血或中性粒细胞减少症那样广为人知，但有效预防和管理血小板减少症对肝病患者也至关重要。
本《消化药理学与治疗学》增刊全面综述了血小板减少症在慢性肝病患者中的重要性、其病理生理学以及与凝血障碍的关系、对临床护理和资源利用的影响，以及可能能够替代血小板输注的新型疗法。
Zotero 插件